ArticleMaterials (Basel, Switzerland)2022
Doxorubicin-Loaded Metal-Organic Framework Nanoparticles as Acid-Activatable Hydroxyl Radical Nanogenerators for Enhanced Chemo/Chemodynamic Synergistic Therapy.
Article in Materials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Advances in metal-organic frameworks (MOFs) for nanotheranostics: from targeted drug delivery to multimodal imaging.Mikrochimica acta · 2026Review
- Redox-modulation of regulated cell death: implications for synergistic anticancer therapies.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Systems-level integration of machine learning, SHAP explainability, PCA, and network topology reveals multitarget protective actions of tannic acid against doxorubicin toxicity in pentose phosphate pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Metal-organic frameworks as therapeutic chameleons: revolutionizing the cancer therapy employing novel nanoarchitectonics.Asian journal of pharmaceutical sciences · 2025Review
- MOF enhances the sensitivity and selectivity of sorafenib as an anticancer drug against hepatocellular carcinoma and colorectal cancer in vitro.Scientific reports · 2025Article
- Nanoscale metal-organic frameworks as a versatile platform for synergistic combination tumor therapy.Journal of nanobiotechnology · 2025Review
- pH-Responsive Nanophotosensitizer Boosting Antibacterial Photodynamic Therapy by Hydroxyl Radical Generation.Nanomaterials (Basel, Switzerland) · 2025Article
- Formation and evaluation of doxorubicin and cromoglycate metal-organic framework for anti-cancer activity.Nanomedicine (London, England) · 2025Article
- Metal-organic frameworks as nanoplatforms for combination therapy in cancer treatment.Medical oncology (Northwood, London, England) · 2024Review
- Current status of Fe-based MOFs in biomedical applications.RSC medicinal chemistry · 2023Review
- Article
- Enhancement of the Solubility of BS Class II Drugs with MOF and MOF/GO Composite Materials: Case Studies of Felodipine, Ketoprofen and Ibuprofen.Materials (Basel, Switzerland) · 2023Article
- LncRNA SLC7A11-AS1 stabilizes CTCF by inhibiting its UBE3A-mediated ubiquitination to promote melanoma metastasis.American journal of cancer research · 2023Article
- A pH-responsive bi-MIL-88B MOF coated with folic acid-conjugated chitosan as a promising nanocarrier for targeted drug delivery of 5-Fluorouracil.Frontiers in pharmacology · 2023Article
- Perspectives of metal-organic framework nanosystem to overcome tumor drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Hydrogen sulfide activatable metal-organic frameworks for Fluorescence Imaging-Guided Photodynamic Therapy of colorectal cancer.Frontiers in bioengineering and biotechnology · 2022Article
- Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Doxorubicin (DOX) is a widely used first-line antitumor agent; however, acquired drug resistance and side effects have become the main challenges to effective cancer therapy. Herein, DOX is loaded into iron-rich metal-organic framework/tannic acid (TA) nanocomplex to form a tumor-targeting and acid-activatable drug delivery system (MOF/TA-DOX, MTD). Under the acidic tumor microenvironment, MTD simultaneously releases DOX and ferrous ion (Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.